Metsera, a wholly owned subsidiary of Pfizer

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Metsera, a wholly owned subsidiary of Pfizer sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 2 currently recruiting 1 completed early-phase tilt upper quartile by trial count

Metsera, a wholly owned subsidiary of Pfizer: 7 sponsored US clinical trials, 2 recruiting.

Metsera, a wholly owned subsidiary of Pfizer sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity and Overweight, with 2 trials.

Upper-quartile sponsor footprint

Metsera, a wholly owned subsidiary of Pfizer sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 3

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

NCT07311850
RECRUITING Phase 1

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

NCT06924320
ACTIVE NOT RECRUITING Phase 2

A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

NCT06973720
ACTIVE NOT RECRUITING Phase 2

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

NCT06897202
ACTIVE NOT RECRUITING Phase 1

A Study of MET233 in Individuals With Obesity or Overweight

NCT07022977
ACTIVE NOT RECRUITING Phase 2

A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight

NCT06712836
COMPLETED Phase 1

This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity

NCT06857617

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3
Phase 3 1

Therapeutic Areas

Obesity and Overweight 2
Overweight or Obesity 2
Obesity 2
Obesity in Diabetes 1
Obesity and Obesity-related Medical Conditions 1
Type 2 Diabetes Mellitus (T2DM) 1

What is open in the Metsera, a wholly owned subsidiary of Pfizer pipeline

2 recruiting of 7 indexed (29% open); 1 completed (14%).

Phase mix: 1 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Obesity and Overweight (2 trials), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Metsera, a wholly owned subsidiary of Pfizer: open-pipeline peers nationwide

Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.

Metsera, a wholly owned subsidiary of Pfizer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30%40% Total trials Recruiting share Metsera, a wholly owned subsidiary of Pfizer3M4Life Research89bioAbbott Diagnostics DivisionAlabama Physical Therapy & AcupunctureAlloSourceAlnylam PharmaceuticalsAnnovis Bio
Metsera, a wholly owned subsidiary of Pfizer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Metsera, a wholly owned subsidiary of Pfizer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 29% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Metsera, a wholly owned subsidiary of Pfizer page

7 registered trials is a research-attention snapshot, not an endorsement of Metsera, a wholly owned subsidiary of Pfizer or any single study.

  • 2 of Metsera, a wholly owned subsidiary of Pfizer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity and Overweight is the condition Metsera, a wholly owned subsidiary of Pfizer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity and Overweight trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Metsera, a wholly owned subsidiary of Pfizer pipeline card: 7 registered trials from official public datasets.Report a data error.